Views 147
Citations 0
Comment & Response
June 2016

In Defense of Off-label Prescribing—Reply

Author Affiliations
  • 1Department of Pharmaceutical Economics and Policy, School of Pharmacy, Massachusetts College of Pharmacy and Health Sciences (MCPHS), Boston
  • 2Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Intern Med. 2016;176(6):861-862. doi:10.1001/jamainternmed.2016.1406

In Reply Unscientific prescribing constitutes 4 of 5 off-label uses,13 and this unscientific prescribing has resulted in a 54% increased risk of adverse drug events compared with on-label uses.2 To crack down on unscientific prescribing, drug regulatory bodies need to demand strong scientific evidence from pharmaceutical companies to safeguard the public.

First Page Preview View Large
First page PDF preview
First page PDF preview